key: cord-0769395-6fz7mu6e
authors: Voruganti, Dinesh; Bassareo, Pier Paolo; Calcaterra, Giuseppe; Mehta, J L
title: Does aspirin save lives in patients with COVID-19?
date: 2021-10-16
journal: Heart
DOI: 10.1136/heartjnl-2021-320255
sha: 3b99c3e1b65d0abad68c39919c89759d2b470b76
doc_id: 769395
cord_uid: 6fz7mu6e

nan

'An aspirin a day keeps the heart attack away', is this also true in the prevention of thrombotic events associated with COVID-19? The rising COVID-19 pandemic has led to much work in the understanding of the pathophysiology of the disease. COVID-19 infection is thought to be an endothelial disease. Supporting this concept, it has been suggested that infection with SARS-CoV-2, the aetiological agent for COVID-19 infection, leads to a state mimicking Virchow's triad, that is, vascular endothelial injury, blood stasis and clotting in concert with systemic inflammation resulting in systemic thrombosis.

In keeping with this concept, moderately and critically ill patients with COVID-19 have been found to have thrombotic and thromboembolic events during the acute and convalescent state. Accordingly, there has been much interest in treating patients with COVID-19 with anticoagulants. In an analysis of several large series of critically ill patients in multiple studies (534 therapeutic anticoagulation, 564 usual care thromboprophylaxis), therapeutic anticoagulation did not improve survival or the number of days free of cardiovascular or respiratory organ support. On the other hand, among 2244 noncritically ill patients (1190 therapeutic anticoagulation, 1054 thromboembolic prophylaxis), therapeutic anticoagulation improved rates of hospital survival and reduced the use of cardiorespiratory organ support. 1 Since there is intense platelet activation secondary to endothelial injury and inflammation, there is also interest in the use of antiplatelet drugs in patients with COVID-19. Currently, recommendations for antiplatelet agents to treat or prevent COVID-19-related thrombotic events are lacking due to absence of data from prospective clinical trials. With multiple mechanisms of tissue protection besides inhibition of platelet aggregation, aspirin may have unexplored potential to treat/prevent COVID-19 complications.

To evaluate the benefit of antiplatelet therapy, Santoro et al 2 selected 7824 patients from the HOPE-COVID-19 registry; 730 (9.3%) received at least one antiplatelet agent (645 aspirin, 33 clopidogrel, 1 ticlopidine and 1 ticagrelor; 35 aspirin and clopidogrel, 10 aspirin and ticagrelor, 5 aspirin and prasugrel). Among 730 patients, 68% were males, 80% had a history of hypertension, 16% had cancer and 68% had an elevation of D-dimer, and in-hospital concomitant anticoagulation was administered in 66% of patients. The multivariate analysis revealed a lower mortality risk (relative risk 0.39, 95% CI 0.32 to 0.48, p<0.01) in patients receiving antiplatelet agents-principally aspirin. No difference was identified for in-hospital mortality or the use of invasive ventilation or bleeding whether patients were given antiplatelet drugs or not.

Several other investigators have evaluated the role of antiplatelet agents in patients with COVID-19 (table 1) . It is of note that the value of these studies is limited by small sample size, retrospective cohorts and lack of homogeneity in the outcomes measured and antiplatelet agent/s used. Furthermore, a study (preprint) by the RECOVERY collaborative group (Horby et al) randomised 14 892 patients with COVID-19 (7351 aspirin and 7541 usual care). 8 This is the only randomised controlled study on aspirin use in patients with COVID-19, which observed that aspirin did not reduce 28-day mortality or the risk of progressing to invasive mechanical ventilation or death. There was a small increase in the rate of being discharged alive within 28 days, bleeding risk and slight reduction in the thrombotic events and duration of hospitalisation among the aspirin group.

The findings of Santoro et al reported in this issue of the journal is the largest retrospective study on aspirin use among patients with COVID-19. However, there are some limitations of the study. Whether or not to give antiplatelet agent and the choice of antiplatelet agent (aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, either with single or dual antiplatelet therapy) was at the discretion of the treating physician, and the mention of major bleeding episode relied on the diagnosis codes. All this brings in the issue of bias. The patients who are admitted are usually elderly with significant comorbidities. Administering aspirin to these patients is subjected to bias, that is, 'confounding by indication', where the real benefits or risks of aspirin may not be truly representative of the whole population.

The study by Santoro et al is a step in the right direction to improve the outcomes of patients with COVID-19. The use of an antiplatelet agent, mainly aspirin, might improve clinical outcomes without increasing the risk of side effects such as bleeding. Aspirin is a safe, cheap, universally available and well-tolerated medication. Using this drug in patients with COVID-19 should be encouraged unless contraindicated. Further, while the most common antiplatelet drug used in these studies was aspirin, a significant number of patients received other antiplatelet agents alone or with aspirin. Thus, it is difficult to state with certainty whether the beneficial effects were related to the use of aspirin with its multiple mechanisms of action and/or the other antiplatelet Table 1 Previous studies with antiplatelet drugs and outcome in patients with COVID-19

Aim of the study Population/methods

Viecca et al 3 Assess the effect of administration of antiplatelet therapy on arterial oxygenation and clinical outcomes in patients with severe COVID-19

Surviving Covid-19 with heparin?

Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation registry

Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Pre-Hospital antiplatelet medication use on COVID-19 disease severity

For the recovery group. aspirin in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, openlabel

Aspirin group: absolute reduction in thrombotic events of 0.6% (SE 0.4%) and an absolute increase in major bleeding events of 0.6% (SE 0.2%).ARDS, acute respiratory distress syndrome; DAPT, dual antiplatelet therapy; MOS, Modified Ordinal Scale.